PloS one · 2025
Lipid accumulation product: A novel marker for gout and hyperuricemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xian Dexian, Wang Wen, Li Hui, Song Geran, Xu Daozheng, Zhang Fengjun, Wang Zhe, Xu Wenchang, Meng Hongyan, Peng Min
Аннотация
BACKGROUND AND AIM: Using cross-sectional data from the 2009-2018 National Health and Nutrition Examination Survey, the purpose of this study was to investigate the potential link between lipid accumulation product and gout/hyperuricemia.
METHODS: The data from 10,871 individuals who participated in the National Health and Nutrition Examination Survey spanning the years 2009-2018 were utilized for additional scrutiny. Participants self-reported gout and hyperuricemia as measured by laboratory test data, and other relevant variables and information for LAP were included. Multivariate logistic regression, restricted cubic spline and p-trend test were employed to determine the association between LAP and gout/hyperuricemia.
RESULTS: The study included 10,871 adults. The prevalence of hyperuricemia and gout was 20.9% and 5.57%, respectively. Compared with the first quartile, the fourth quartile of lipid accumulation product was associated with a 271% higher risk of hyperuricemia (OR = 3.711, 95% CI 2.732-5.042, p < 0.001) in a fully adjusted model. A similar association was found between continuous increase in lipid accumulation product and hyperuricemia (OR = 2.441, 95%CI = 1.348-4.42, p = 0.005), with p trends showing both < 0.001. The RCS model suggests a significant non-linear relationship between lipid accumulation product and the risk of gout/hyperuricemia. There was an inverted U-shaped relationship between lipid accumulation product and gout/hyperuricemia.
CONCLUSIONS: This study confirmed that lipid accumulation product has a high potential to predict the risk of gout/hyperuricemia. These findings suggested that the adjustment of the degree of fat accumulation may be a potential way to prevent and control the onset of gout/hyperuricemia.
METHODS: The data from 10,871 individuals who participated in the National Health and Nutrition Examination Survey spanning the years 2009-2018 were utilized for additional scrutiny. Participants self-reported gout and hyperuricemia as measured by laboratory test data, and other relevant variables and information for LAP were included. Multivariate logistic regression, restricted cubic spline and p-trend test were employed to determine the association between LAP and gout/hyperuricemia.
RESULTS: The study included 10,871 adults. The prevalence of hyperuricemia and gout was 20.9% and 5.57%, respectively. Compared with the first quartile, the fourth quartile of lipid accumulation product was associated with a 271% higher risk of hyperuricemia (OR = 3.711, 95% CI 2.732-5.042, p < 0.001) in a fully adjusted model. A similar association was found between continuous increase in lipid accumulation product and hyperuricemia (OR = 2.441, 95%CI = 1.348-4.42, p = 0.005), with p trends showing both < 0.001. The RCS model suggests a significant non-linear relationship between lipid accumulation product and the risk of gout/hyperuricemia. There was an inverted U-shaped relationship between lipid accumulation product and gout/hyperuricemia.
CONCLUSIONS: This study confirmed that lipid accumulation product has a high potential to predict the risk of gout/hyperuricemia. These findings suggested that the adjustment of the degree of fat accumulation may be a potential way to prevent and control the onset of gout/hyperuricemia.